Your browser doesn't support javascript.
loading
A new brief opioid stigma scale to assess perceived public attitudes and internalized stigma: Evidence for construct validity.
Yang, Lawrence H; Grivel, Margaux M; Anderson, Bradley; Bailey, Genie L; Opler, Mark; Wong, Liang Yi; Stein, Michael D.
Afiliação
  • Yang LH; Department of Social and Behavioral Sciences, College of Global Public Health, New York University, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, NY, USA. Electronic address: Ly1067@nyu.edu.
  • Grivel MM; Department of Social and Behavioral Sciences, College of Global Public Health, New York University, NY, USA.
  • Anderson B; Butler Hospital, Providence, RI, USA.
  • Bailey GL; Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, RI, USA; Stanley Street Treatment & Resources, Inc., Fall River, MA, USA.
  • Opler M; MedAvante-ProPhase Inc., USA.
  • Wong LY; City College of New York, NY, USA.
  • Stein MD; Butler Hospital, Providence, RI, USA; Boston University School of Public Health, Boston, MA, USA.
J Subst Abuse Treat ; 99: 44-51, 2019 04.
Article em En | MEDLINE | ID: mdl-30797393
ABSTRACT
One key strategy to improve treatment access for persons with opioid use disorder (OUD) is overcoming stigma that is internalized by such individuals. Because few theoretically-derived, multidimensional measures of substance abuse stigma exist, we contribute a brief, theoretically-based measure of opioid-related stigma (adapted from Corrigan's Self-Stigma of Mental Illness Scale) to assess perceived stigma and internalized stigma among individuals with OUD. This study presents initial validation of the newly-developed Brief Opioid Stigma Scale among 387 adults who entered an inpatient opioid managed-withdrawal program. The scale assesses (1) Stereotype awareness ("Aware"), or the extent to which individuals who use opioids perceive community members to believe OUD-related stereotypes; (2) Stereotype agreement ("Agree"), or the endorsement of stigmatizing beliefs by individuals who use opioids; (3) Self-esteem decrement ("Harm"), or the diminution of self-esteem due to these negative stereotypes' impacts on self-worth. Psychosocial measures including self-esteem, depressive symptoms, mental and physical functioning, and desire for aftercare OUD medication treatment, were administered to assess construct validity. Results showed that greater endorsement of the "harm" stigma subscale was associated with greater depressive symptoms, lower self-esteem, and poorer mental and physical functioning. The "aware" stigma subscale displayed similar overall patterns of associations with self-esteem and depression but to a lesser magnitude. The "aware" stigma subscale was positively associated with desire for aftercare methadone and naltrexone treatment, and the "harm" subscale was positively associated with desire for aftercare buprenorphine treatment. Results indicated good initial construct validity. Tailored stigma interventions are recommended for specific aftercare OUD medication treatments.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Opinião Pública / Estigma Social / Pacientes Internados / Transtornos Relacionados ao Uso de Opioides Limite: Adult / Female / Humans / Male Idioma: En Revista: J Subst Abuse Treat Assunto da revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Opinião Pública / Estigma Social / Pacientes Internados / Transtornos Relacionados ao Uso de Opioides Limite: Adult / Female / Humans / Male Idioma: En Revista: J Subst Abuse Treat Assunto da revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Ano de publicação: 2019 Tipo de documento: Article